After shares of Novo Nordisk (NVO) fell throughout the last year, the more recent drop may be its last. The company, along with its rival Eli Lilly (LLY), will offer its obesity drug for $499 per ...

We do believe that people who face high out-of-pocket costs need more options,” said Kevin Donahoe, diabetes marketing chief for Novo Nordisk. Plus: a look at the drugmaker's alliance with GoodRx; how ...